These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24769627)
1. Disruption of cerebrospinal fluid flow through the olfactory system may contribute to Alzheimer's disease pathogenesis. Ethell DW J Alzheimers Dis; 2014; 41(4):1021-30. PubMed ID: 24769627 [TBL] [Abstract][Full Text] [Related]
3. Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: a hypothesis. Wostyn P; van Dam D; Audenaert K; de Deyn PP J Neurogenet; 2011 Dec; 25(4):195-200. PubMed ID: 22023247 [TBL] [Abstract][Full Text] [Related]
4. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients. Sancesario GM; Cencioni MT; Esposito Z; Borsellino G; Nuccetelli M; Martorana A; Battistini L; Sorge R; Spalletta G; Ferrazzoli D; Bernardi G; Bernardini S; Sancesario G J Alzheimers Dis; 2012; 31(4):865-78. PubMed ID: 22717612 [TBL] [Abstract][Full Text] [Related]
5. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781 [TBL] [Abstract][Full Text] [Related]
6. Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's disease patients. Bibl M; Gallus M; Welge V; Esselmann H; Wiltfang J J Alzheimers Dis; 2012; 29(4):809-16. PubMed ID: 22460324 [TBL] [Abstract][Full Text] [Related]
7. How well does the CSF inform upon pathology in the brain in Creutzfeldt-Jakob and Alzheimer's diseases? Weller RO J Pathol; 2001 May; 194(1):1-3. PubMed ID: 11329133 [TBL] [Abstract][Full Text] [Related]
8. Age-related changes in brain extracellular space affect processing of amyloid-β peptides in Alzheimer's disease. Bondareff W J Alzheimers Dis; 2013; 35(1):1-6. PubMed ID: 23364138 [TBL] [Abstract][Full Text] [Related]
9. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease. Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
11. Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Maia LF; Kaeser SA; Reichwald J; Hruscha M; Martus P; Staufenbiel M; Jucker M Sci Transl Med; 2013 Jul; 5(194):194re2. PubMed ID: 23863834 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro. Ono K; Noguchi M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M Neurobiol Dis; 2005 Nov; 20(2):233-40. PubMed ID: 16242632 [TBL] [Abstract][Full Text] [Related]
13. The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid-β, and Sleep. Boespflug EL; Iliff JJ Biol Psychiatry; 2018 Feb; 83(4):328-336. PubMed ID: 29279202 [TBL] [Abstract][Full Text] [Related]
14. Amyloid-β deposition and olfactory dysfunction in an Alzheimer's disease model. Wu N; Rao X; Gao Y; Wang J; Xu F J Alzheimers Dis; 2013; 37(4):699-712. PubMed ID: 23948910 [TBL] [Abstract][Full Text] [Related]
15. The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. Wang-Dietrich L; Funke SA; Kühbach K; Wang K; Besmehn A; Willbold S; Cinar Y; Bannach O; Birkmann E; Willbold D J Alzheimers Dis; 2013; 34(4):985-94. PubMed ID: 23313925 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Maddalena AS; Papassotiropoulos A; Gonzalez-Agosti C; Signorell A; Hegi T; Pasch T; Nitsch RM; Hock C Neurodegener Dis; 2004; 1(4-5):231-5. PubMed ID: 16908995 [TBL] [Abstract][Full Text] [Related]
17. Single particle detection of Abeta aggregates associated with Alzheimer's disease. Funke SA; Birkmann E; Henke F; Görtz P; Lange-Asschenfeldt C; Riesner D; Willbold D Biochem Biophys Res Commun; 2007 Dec; 364(4):902-7. PubMed ID: 17963690 [TBL] [Abstract][Full Text] [Related]
18. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid from Alzheimer's disease patients promotes amyloid beta-protein oligomerization. Ikeda T; Ono K; Elashoff D; Condron MM; Noguchi-Shinohara M; Yoshita M; Teplow DB; Yamada M J Alzheimers Dis; 2010; 21(1):81-6. PubMed ID: 20413863 [TBL] [Abstract][Full Text] [Related]